Restoration of cellular apoptotic pathways plays a crucial role in cancer therapy strategies. In a broad spectrum of anticancer drugs, epigenetic effectors are in the center of interest mostly because of potential reversibility of their action. Methylation status of the cells is influenced by methyltransferase inhibitor 2-deoxy-5'-azacytidine (decitabine, DAC), but higher concentrations of this agent cause a DNA-damage. In our study, tumor supressor p53-apoptotic pathway was activated in decitabine-induced cell death. Expression of p53-inducible BH3-only apoptotic proteins Puma and Noxa was elevated and large activation of executive caspases was observed. The extent of acetylation in the cell is affected by histonedeacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Combination of SAHA with decitabine brought synergistic effect on apoptosis triggering in CML-T1 cell line, but apoptosis as well as necrosis occurred also in normal peripheral blood lymphocytes. Therefore, promising potential of such combined therapy calls for more detailed investigation of unwanted effects in normal cells.

Institute of Hematology and Blood Transfusion Prague 2 Czech Republic

Erratum v

Mol Cell Biochem. 2012 Jun;365(1-2):379 PubMed

Zobrazit více v PubMed

Mol Cell Biol. 2008 Sep;28(17):5391-402 PubMed

Leuk Res. 2009 Dec;33 Suppl 2:S2-6 PubMed

Cancer. 2008 Jun;112(11):2341-51 PubMed

Urology. 2008 Jun;71(6):1220-5 PubMed

Blood. 2010 Mar 25;115(12):2430-40 PubMed

Mol Pharmacol. 2008 Mar;73(3):1005-12 PubMed

J Cell Biochem. 2006 Aug 1;98(5):1230-48 PubMed

EMBO J. 2001 Mar 15;20(6):1331-40 PubMed

J Biol Chem. 2009 Apr 24;284(17):11171-83 PubMed

Ann Hematol. 2005 Dec;84 Suppl 1:47-53 PubMed

Curr Opin Cell Biol. 2005 Dec;17(6):617-25 PubMed

Cell Mol Life Sci. 2009 Apr;66(8):1326-36 PubMed

Mol Pharmacol. 2009 Nov;76(5):1072-81 PubMed

Anticancer Drugs. 2007 Aug;18(7):763-72 PubMed

Mol Cell. 2005 Feb 4;17(3):393-403 PubMed

Cancer Res. 2009 Feb 1;69(3):887-95 PubMed

Int J Cancer. 2007 Aug 1;121(3):656-65 PubMed

Leuk Res. 2006 Jan;30(1):69-76 PubMed

Mol Cell Biol. 2006 Apr;26(7):2782-90 PubMed

Int J Biochem Cell Biol. 2009 Jan;41(1):72-80 PubMed

Int J Biochem Cell Biol. 2005 Feb;37(2):267-71 PubMed

Haematologica. 2010 Feb;95(2):303-10 PubMed

Lung Cancer. 2009 Nov;66(2):184-90 PubMed

Oncogene. 2008 Jun 5;27(25):3615-23 PubMed

Recent Results Cancer Res. 2010;184:131-57 PubMed

Blood. 2009 Apr 30;113(18):4281-8 PubMed

Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20 PubMed

J Cell Biol. 2007 Nov 19;179(4):701-15 PubMed

Cancer Lett. 2009 Aug 8;280(2):192-200 PubMed

Int J Oncol. 2008 Oct;33(4):767-76 PubMed

Eur J Haematol. 2008 Feb;80(2):133-42 PubMed

Mol Cancer Ther. 2007 Jun;6(6):1718-27 PubMed

Eur J Cancer. 2009 Sep;45(13):2402-11 PubMed

Haematologica. 2010 Apr;95(4):613-21 PubMed

Biochem Biophys Res Commun. 2009 Oct 16;388(2):418-21 PubMed

Genes Chromosomes Cancer. 2009 Jan;48(1):10-21 PubMed

Int J Oncol. 2008 Jan;32(1):177-84 PubMed

Int J Biochem Cell Biol. 2004 Feb;36(2):223-34 PubMed

Cancer Invest. 2008 Aug;26(7):680-8 PubMed

World J Surg Oncol. 2009 May 21;7:49 PubMed

Semin Hematol. 2005 Jul;42(3 Suppl 2):S17-22 PubMed

Curr Mol Med. 2008 Mar;8(2):138-47 PubMed

Blood. 2008 Sep 1;112(5):2013-6 PubMed

Mol Cancer Res. 2005 Jun;3(6):325-34 PubMed

PLoS One. 2008 Jun 18;3(6):e2445 PubMed

Expert Opin Ther Targets. 2007 Mar;11(3):363-73 PubMed

Leukemia. 2002 Apr;16(4):433-43 PubMed

PLoS One. 2010 Sep 14;5(9):e12417 PubMed

J Cell Biol. 2009 Apr 20;185(2):279-90 PubMed

J Cell Biochem. 2010 Jan 1;109(1):184-95 PubMed

Int J Cancer. 2009 Sep 1;125(5):1168-76 PubMed

Clin Cancer Res. 2009 Jun 15;15(12):3938-46 PubMed

J Biol Chem. 2008 Feb 1;283(5):2564-74 PubMed

Leuk Res. 2003 Nov;27(11):999-1007 PubMed

Br J Cancer. 2009 Mar 10;100(5):758-63 PubMed

Blood. 2009 Jan 15;113(3):659-67 PubMed

Mol Cell Biol. 2008 Jan;28(2):752-71 PubMed

Curr Opin Oncol. 2008 Nov;20(6):705-10 PubMed

Int J Biochem Cell Biol. 2007;39(5):1016-25 PubMed

Cell Biochem Funct. 2009 Apr;27(3):167-75 PubMed

Combined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytes

Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors